Arts

Books

Fashion & Beauty

Performing Arts

Food

Visual Arts

Design

Business

Entrepreneurship

Investing

Marketing

Careers

Management

Non-Profit

Comedy

Stand-Up

Comedy Interviews

Improv

Education

Self-Improvement

How To

Courses

Language Learning

Fiction

Comedy Fiction

Drama

Science Fiction

Government

Health & Fitness

Medicine

Alternative Health

Nutrition

Mental Health

Fitness

Sexuality

History

Kids & Family

Parenting

Stories for Kids

Education for Kids

Pets & Animals

Leisure

Video Games

Games

Automotive

Animation & Manga

Hobbies

Aviation

Home & Garden

Crafts

Music

Music Commentary

Music Interviews

Music History

News

Sports News

Entertainment News

News Commentary

Politics

Daily News

Business News

Tech News

Religion & Spirituality

Christianity

Spirituality

Religion

Judaism

Islam

Buddhism

Hinduism

Science

Social Sciences

Life Sciences

Natural Sciences

Nature

Chemistry

Mathematics

Earth Sciences

Physics

Astronomy

Society & Culture

Documentary

Relationships

Philosophy

Personal Journals

Places & Travel

Sports

Golf

Soccer

Wrestling

Basketball

Football

Fantasy Sports

Baseball

Wilderness

Running

Hockey

Rugby

Cricket

Volleyball

Tennis

Swimming

Technology

True Crime

TV & Film

Film Interviews

TV Reviews

After Shows

Film Reviews

Film History

O podcast cinética é um guia conciso para quem tem pressa, porém, é abrangente, de tudo o que precisamos saber, desde os mistérios da teoria da relatividade a biodiversidade do Brasil. Aumente o som, aperte o play e sinta a reação cinética que vem por ai já neste primeiro episódio

Cinética

Informar a las personas sobre las Energías renovables

Las Energías renovables

We invite you "behind the science" with SLAS Discovery Editorial Board Member and Podcast Editor Rob Howes, Ph.D. (Rosalind Franklin Laboratory, Leamington Spa, UK) to hear from our featured SLAS Discovery authors! This podcast series is a chance for readers to meet the people behind the journal science and hear directly from them about their work, their motivations, as well as the context and potential impact of their work. Watch for a new featured author interview with each SLAS Discovery Special Issue, as well as interviews with other people who impact the journal.

SLAS Discovery Author Insights

El astrónomo Néstor Espinoza conversa con Freddy Stock sobre todo lo que sabemos, y lo que no sabemos sobre la galaxia, las constelaciones y en general, el espacio exterior.

Razones siderales

Ohjelmassa keskustellaan asiantuntijoiden kanssa joustavuudesta matematiikassa ja matematiikan opetuksessa.

Jouheva joustavuus matematiikassa

Podcast Jc

This podcast by Mathias Pickl and Christoph Winkler officially accompanies the Biotrans 2021 conference in Graz. Meet here the scientists who were invited to give a lecture at the meeting and are among the brightest minds in the field. Talking science without graphical aids gives a unique opportunity to address a broader perspective and to get to know the researchers in a new way. (The Podcast "In the Active Site" is released under a CC-BY license)

In the Active Site

&#128105;&#8205;&#128300;&#8217;Las científicas del coronavirus. Retratos sonoros de una pandemia&#8217;. 
Una audioserie de Núria Jar para Agencia SINC realizada con fondos de emergencia para periodistas de la National Geographic Society.
Montaje: Andreu Quesada.

👩‍🔬’Las científicas del coronavirus. Retratos sonoros de una pandemia’. Una audioserie de Núria Jar para Agencia SINC realizada con fondos de emergencia para periodistas de la National Geographic Society. Montaje: Andreu Quesada.

👩‍🔬’Las científicas del coronavirus. Retratos sonoros de una pandemia’. 
Una audioserie de Núria Jar para Agencia SINC realizada con fondos de emergencia para periodistas de la National Geographic Society.
Montaje: Andreu Quesada.

Las científicas del coronavirus

In jeder Folge stellen wir euch einen Algorithmus vor. Dabei orientieren wir uns am Anfang an einer Algorithmen-Vorlesung unseres Lehrstuhls, mal sehen was später noch daraus wird.

Algo2Go

Podcastmais

High Maintenance is a feel good podcast, a place where you can sit back, get a little giggly, and learn about the universe so simply that stoned girls understand it. So come join(t) hosts Fionnah, Cam and Liz getting spaced out!!

High Maintenance

Episodio Sociedades

My. Psikolojiye hoş geldiniz. Aman dikkat edin bu sayfada Psikolojiye dair her şey yer alıyor. BU bilgiler sizi mutlu da edebilir üzüntülü de ama en sonunda mutlaka bilgi edinirsiniz. Günde bir kereden fazla bu podcastler in dinlenilmemesi Psikolojik Danışman Miraç Yoldaş tarafından şiddetle tavsiye edilmektedir. Keyifli Dinlemeler.
Bilgi almak için; https://linktr.ee/pdmiracyoldas

My. Psikolojiye hoş geldiniz. Aman dikkat edin bu sayfada Psikolojiye dair her şey yer alıyor. BU bilgiler sizi mutlu da edebilir üzüntülü de ama en sonunda mutlaka bilgi edinirsiniz. Günde bir kereden fazla bu podcastler in dinlenilmemesi Psikolojik Danışman Miraç Yoldaş tarafından şiddetle tavsiye edilmektedir. Keyifli Dinlemeler. Bilgi almak için; https://linktr.ee/pdmiracyoldas

My. Psikoloji

Somos un grupo de estudiantes, con las ganas de compartir información de nuestras carreras y opiniones sobre temas de biociencias.

Los Bioinges Podcast

Addiction Practice Pod is a podcast series on addiction and substance use care for health care providers, offering practical tips and guidance to improve addiction care.

Addiction Practice Pod

Unter 4 Augen - der Ophtha-Podcast ist das neue Audioformat der Augenheilkunde.

Medical Retina, Glaukom, moderne Kataraktchirurgie, Genetik oder Onkologie -
die Ophthalmologie ist ein weites Feld. 

Unter 4 Augen - der Ophtha-Podcast  präsentiert jeden Monat ein neues Thema in vier Ausgaben. Zu jedem Thema laden wir renommierte Experten ein, die spannende und aktuelle wissenschaftliche Arbeiten vorstellen. Gemeinsam mit unserem jungen Moderatorenteam, das als Assistenzärzte oder Medizinstudierende bereits erste Erfahrungen in der Ophthalmologie gesammelt hat, analysieren unsere Experten im Gespräch verschiedene Studien und gehen deren Thesen auf den Grund. 
Der Wissenstransfer steht bei diesem Format im Fokus.

Ab dem 04. September 2021 erscheinen wöchentlich vier Folgen zu einem Themenmonat. Jede Folge hat eine Länge von etwa 15 Minuten. 

Unter 4 Augen - der Ophtha-Podcast bringt die Ergebnisse wissenschaftlicher
Arbeiten auf eine praxisnahe und klinisch relevante Ebene. 
Unsere Zielgruppe besteht aus Medizinstudierenden, Assistenzärztinnen und Assistenzärzten, junge Fachärztinnen und Fachärzten, aber natürlich auch bereits etablierten und erfahrenen Ophthalmologen, die Interesse an wissenschaftlicher Augenheilkunde haben.

Unter 4 Augen - der Ophtha-Podcast  wird produziert von Tobias Kesting, Geschäftsführer der Agentur Carekom in Köln. 
Die wissenschaftliche Leitung übernimmt Prof. Dr. Alireza Mirshahi, Direktor der Augenklinik Dardenne.

Moderation: Annika Licht

Unter 4 Augen - der Ophtha-Podcast ist das neue Audioformat der Augenheilkunde. Medical Retina, Glaukom, moderne Kataraktchirurgie, Genetik oder Onkologie - die Ophthalmologie ist ein weites Feld. Unter 4 Augen - der Ophtha-Podcast präsentiert jeden Monat ein neues Thema in vier Ausgaben. Zu jedem Thema laden wir renommierte Experten ein, die spannende und aktuelle wissenschaftliche Arbeiten vorstellen. Gemeinsam mit unserem jungen Moderatorenteam, das als Assistenzärzte oder Medizinstudierende bereits erste Erfahrungen in der Ophthalmologie gesammelt hat, analysieren unsere Experten im Gespräch verschiedene Studien und gehen deren Thesen auf den Grund. Der Wissenstransfer steht bei diesem Format im Fokus. Ab dem 04. September 2021 erscheinen wöchentlich vier Folgen zu einem Themenmonat. Jede Folge hat eine Länge von etwa 15 Minuten. Unter 4 Augen - der Ophtha-Podcast bringt die Ergebnisse wissenschaftlicher Arbeiten auf eine praxisnahe und klinisch relevante Ebene. Unsere Zielgruppe besteht aus Medizinstudierenden, Assistenzärztinnen und Assistenzärzten, junge Fachärztinnen und Fachärzten, aber natürlich auch bereits etablierten und erfahrenen Ophthalmologen, die Interesse an wissenschaftlicher Augenheilkunde haben. Unter 4 Augen - der Ophtha-Podcast wird produziert von Tobias Kesting, Geschäftsführer der Agentur Carekom in Köln. Die wissenschaftliche Leitung übernimmt Prof. Dr. Alireza Mirshahi, Direktor der Augenklinik Dardenne. Moderation: Annika Licht

Unter 4 Augen - der Wissenschaftspodcast der Ophthalmologie

Radio Amonite

A monthly podcast that aims to empower the next generation of science, technology, engineering and mathematic (STEM) innovators. Join Shubh Patel, a Schulich Leader scholar and a STEM Fellowship member, to spark big ideas with prominent STEM leaders.

STEMFellows

🧠 « EurêKa » : les super-pouvoirs de notre cerveau , avec Stéphane Zunino !  

Dans cette chronique diffusée sur LYON 1ère, au travers de conseils d’ experts en sciences cognitives et d’ invités, nous allons comprendre comment mieux utiliser notre cerveau en s' appuyant sur les sciences cognitives pour améliorer la façon de penser et d'agir des individus tant dans la sphère privée que professionnelle. 
 
Avec notre partenaire Cognidia  (https://www.cognidia.fr/) (facilitation et formations en sciences cognitives et innovation), un projet de la Cellule innovation de Groupama Rhône-Alpes Auvergne.

🎧 Ecoutez LYON 1ERE 🎵 sur lyonpremiere.fr, l'application et à Lyon sur 90.2FM et en DAB+.
Hébergé par Ausha. Visitez ausha.co/fr/politique-de-confidentialite pour plus d'informations.

🧠 « EurêKa » : les super-pouvoirs de notre cerveau , avec Stéphane Zunino ! Dans cette chronique diffusée sur LYON 1ère, au travers de conseils d’ experts en sciences cognitives et d’ invités, nous allons comprendre comment mieux utiliser notre cerveau en s' appuyant sur les sciences cognitives pour améliorer la façon de penser et d'agir des individus tant dans la sphère privée que professionnelle. Avec notre partenaire Cognidia (https://www.cognidia.fr/) (facilitation et formations en sciences cognitives et innovation), un projet de la Cellule innovation de Groupama Rhône-Alpes Auvergne. 🎧 Ecoutez LYON 1ERE 🎵 sur lyonpremiere.fr, l'application et à Lyon sur 90.2FM et en DAB+. Hébergé par Ausha. Visitez ausha.co/fr/politique-de-confidentialite pour plus d'informations.

🧠 « EurêKa » : les super-pouvoirs de notre cerveau , avec Stéphane Zunino ! &nbsp;

Dans cette chronique diffusée sur LYON 1ère, au travers de conseils d’ experts en sciences cognitives et d’ invités, nous allons comprendre comment mieux utiliser notre cerveau en s' appuyant sur les sciences cognitives pour améliorer la façon de penser et d'agir des individus tant dans la sphère privée que professionnelle.&nbsp;
&nbsp;
Avec notre partenaire Cognidia  (https://www.cognidia.fr/)&nbsp;(facilitation et formations en sciences cognitives et innovation), un projet de la Cellule innovation de Groupama Rhône-Alpes Auvergne.

🎧 Ecoutez LYON 1ERE 🎵 sur lyonpremiere.fr, l'application et à Lyon sur 90.2FM et en DAB+.
Hébergé par Ausha. Visitez ausha.co/fr/politique-de-confidentialite pour plus d'informations.

EURÊKA | Les super-pouvoirs de notre cerveau

Caroberts88877

《认知心理学》（第8版）是关于认知心理学的基础知识和研究成果，由美国心理学家索尔所教授所著。该书涵盖了感觉、知觉、注意、记忆、意识、知识表征、概念形成、推理、决策、问题解决、创造、人类智力、语言以及人工智能等。书中不仅介绍了大量经典的认知心理学实验，而且对认知神经科学的研究成果给与了高度重视和充分表述。

《认知心理学》（第8版）是关于认知心理学的基础知识和研究成果，由美国心理学家索尔所教授所著。该书涵盖了感觉、知觉、注意、记忆、意识、知识表征、概念形成、推理、决策、问题解决、创造、人类智力、语言以及人工智能等。书中不仅介绍了大量经典的认知心理学实验，而且对认知神经科学的研究成果给与了高度重视和充分表述。

《认知心理学》（第8版）是关于认知心理学的基础知识和研究成果，由美国心理学家索尔所教授所著。该书涵盖了感觉、知觉、注意、记忆、意识、知识表征、概念形成、推理、决策、问题解决、创造、人类智力、语言以及人工智能等。书中不仅介绍了大量经典的认知心理学实验，而且对认知神经科学的研究成果给与了高度重视和充分表述。

认知心理学：开启认识世界的全新大门

A lo legal: Derecho y actualidad es un espacio creado por el Departamento de Estudios Jurídicos de la Universidad Icesi con el apoyo de la Organización de Estudiantes de Derecho de Icesi y el Semillero de Transformación Digital, el cual tiene por objetivo ser un canal de interacción entre docentes, estudiantes y la sociedad en general.Durante los próximos minutos conversaremos con diversos invitados sobre cuestiones de actualidad en el mundo del derechoUtilizaremos un lenguaje claro, sencillo y ameno, que nos permitirán identificar y explicar los temas relevantes en el mundo del derecho.

A lo legal: Derecho y actualidad es un espacio creado por el Departamento de Estudios Jurídicos de la Universidad Icesi con el apoyo de la Organización de Estudiantes de Derecho de Icesi y el Semillero de Transformación Digital, el cual tiene por objetivo ser un canal de interacción entre docentes, estudiantes y la sociedad en general. Durante los próximos minutos conversaremos con diversos invitados sobre cuestiones de actualidad en el mundo del derecho Utilizaremos un lenguaje claro, sencillo y ameno, que nos permitirán identificar y explicar los temas relevantes en el mundo del derecho.

A lo legal: Derecho y actualidad

In de Vogelboekenpodcast van Vogelbescherming interviewen we auteurs van vogelboeken. Ook tippen we klassiekers en laatste gelezen boeken. Wij zijn Arjan Berben, co-hoofredacteur van het blad Vogels, en Gert Ottens, verklaard ornitho-bibliofiel en ook werkzaam bij Vogelbescherming. We zitten in de serre van onze gezellige winkel in Zeist.

Vogelboekenpodkast

Une émission pour tenter de mieux comprendre notre monde dans son versant politique et social, à travers les théories en sciences humaines et en philosophie, les pratiques, les auteurs et autrices, les doctrines et les pensées d’hier et d’aujourd’hui. Vous pouvez soutenir le projet sur Patreon ou Kiss kiss bank bank. <hr> Hébergé par Acast. Visitez <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> pour plus d'informations.

Une émission pour tenter de mieux comprendre notre monde dans son versant politique et social, à travers les théories en sciences humaines et en philosophie, les pratiques, les auteurs et autrices, les doctrines et les pensées d’hier et d’aujourd’hui. Vous pouvez soutenir le projet sur Patreon ou Kiss kiss bank bank. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Une émission pour tenter de mieux comprendre notre monde dans son versant politique et social, à travers les théories en sciences humaines et en philosophie, les pratiques, les auteurs et autrices, les doctrines et les pensées d’hier et d’aujourd’hui. Vous pouvez soutenir le projet sur Patreon ou Kiss kiss bank bank. Hébergé par Acast. Visitez <a href="https://acast.com/privacy" rel="noopener noreferrer">acast.com/privacy</a> pour plus d'informations.

Politikon

پۆدکاستێکی گەنجانەی تایبەتە بە شێوازی پێشکێشکردنی پرۆژەی کار،  داواکردنی کار و چۆنیەتی دەستکەوتی دەرفەتی کار لە دامەزراوە جیاوازەکانی هەرێمی کوردستان و رێکخراوە نێودەوڵەتییەکان، هەفتانە کازیوە لەگەڵ میوانەکەی باسی دەستپیشخەرییەکانی کار، چۆنیەتی خۆئامادەکردن بۆ چاوپێکەوتنی کار، پێشکێشکردنی پرۆژە و پەیداکردنی پشتگیری بۆ پرۆژەکان دەکات

پۆدکاستێکی گەنجانەی تایبەتە بە شێوازی پێشکێشکردنی پرۆژەی کار، داواکردنی کار و چۆنیەتی دەستکەوتی دەرفەتی کار لە دامەزراوە جیاوازەکانی هەرێمی کوردستان و رێکخراوە نێودەوڵەتییەکان، هەفتانە کازیوە لەگەڵ میوانەکەی باسی دەستپیشخەرییەکانی کار، چۆنیەتی خۆئامادەکردن بۆ چاوپێکەوتنی کار، پێشکێشکردنی پرۆژە و پەیداکردنی پشتگیری بۆ پرۆژەکان دەکات

سیڤی لاین

San Diego Weather Daily is your essential daily podcast for the latest weather forecasts in San Diego, California. This podcast provides concise and accurate weather updates each morning, ensuring you are well-prepared for the day ahead in this beautiful coastal city. Known for its mild, year-round climate, San Diego experiences subtle weather changes that our podcast carefully details. From the sunny, warm beaches to the occasional foggy mornings, we cover everything you need to know about temperature trends, cloud coverage, and the rare rainy days. Whether you’re planning a day at the beach, a visit to Balboa Park, or navigating the city's diverse neighborhoods, our updates will help you plan effectively. We also offer insights into how the weather might impact local surf conditions, outdoor events, and your daily commute. Tune in to San Diego Weather Daily for a reliable, daily dose of San Diego’s weather, tailored to fit the unique lifestyle of America’s Finest City.

Subscribe and start your day with a forecast that's as dynamic as our city! Note: Every element of this Podcast is proudly powered by AI and a fun, dynamic experiment being evolved by AI Strategist Jim Carter III (jimcarter.me). For features/sponsorship opportunities email media@fastfoundations.com!

San Diego Weather Daily is your essential daily podcast for the latest weather forecasts in San Diego, California. This podcast provides concise and accurate weather updates each morning, ensuring you are well-prepared for the day ahead in this beautiful coastal city. Known for its mild, year-round climate, San Diego experiences subtle weather changes that our podcast carefully details. From the sunny, warm beaches to the occasional foggy mornings, we cover everything you need to know about temperature trends, cloud coverage, and the rare rainy days. Whether you’re planning a day at the beach, a visit to Balboa Park, or navigating the city's diverse neighborhoods, our updates will help you plan effectively. We also offer insights into how the weather might impact local surf conditions, outdoor events, and your daily commute. Tune in to San Diego Weather Daily for a reliable, daily dose of San Diego’s weather, tailored to fit the unique lifestyle of America’s Finest City. Subscribe and start your day with a forecast that's as dynamic as our city! Note: Every element of this Podcast is proudly powered by AI and a fun, dynamic experiment being evolved by AI Strategist Jim Carter III (jimcarter.me). For features/sponsorship opportunities email media@fastfoundations.com!

San Diego Weather Daily

Har du noen ganger møtt påstander du lurer på om stemmer? Med denne podkasten ønsker vi å bidra på vår måte til mer refleksjon og bedre undervisning. Episodene vil ha ulike temaer, men mange vil handle om myter og misforståelser som vi dessverre kan finne i læremidler og populærvitenskap, på skolebiblioteket og i sosiale media."Lurt av læreboken?" er en podkast fra <a target="_blank" rel="noopener noreferrer nofollow" href="http://Fagsjekk.no">Fagsjekk.no</a>. Har du noen spørsmål til oss? Send oss en mail til <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:fagsjekk@nkss.no">post@fagsjekk.no</a>

Har du noen ganger møtt påstander du lurer på om stemmer? Med denne podkasten ønsker vi å bidra på vår måte til mer refleksjon og bedre undervisning. Episodene vil ha ulike temaer, men mange vil handle om myter og misforståelser som vi dessverre kan finne i læremidler og populærvitenskap, på skolebiblioteket og i sosiale media. "Lurt av læreboken?" er en podkast fra Fagsjekk.no. Har du noen spørsmål til oss? Send oss en mail til post@fagsjekk.no

Har du noen ganger møtt påstander du lurer på om stemmer? Med denne podkasten ønsker vi å bidra på vår måte til mer refleksjon og bedre undervisning. Episodene vil ha ulike temaer, men mange vil handle om myter og misforståelser som vi dessverre kan finne i læremidler og populærvitenskap, på skolebiblioteket og i sosiale media."Lurt av læreboken?" er en podkast fra <a href="http://Fagsjekk.no" rel="noopener noreferrer">Fagsjekk.no</a>. Har du noen spørsmål til oss? Send oss en mail til <a href="mailto:fagsjekk@nkss.no" rel="noopener noreferrer">post@fagsjekk.no</a>

Lurt av læreboken?

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside wit

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside wit

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside wit

Malaria Vaccine

Um canal dedicado à divulgação de notícias do setor aquícola, proporcionando debates claros e concisos sobre uma ampla gama de temas relacionados à aquicultura.

De 0 a 100 na Aquicultura

در طول این پادکست، من «مهدی شفا» یک‌ کتاب‌ غیر‌‌داستانی مربوط‌ به ژنتیک، فرگشت، مغز، ذهن و‌رفتار‌انسان ‌رو خلاصه و‌ خدمت شما تعریف میکنم. این تلاشی است در جهت افزایش آگاهی، تفکر نقادانه و‌ سنجشگر و‌ بینش علمی در بین فارسی زبانان.&nbsp; &nbsp; Summarizing and explaining books related to human brain, biology, Genetics, evolution and behavior.&nbsp; Trying to promote scientific and critical thinking among Farsi-speaking people.&nbsp;

در طول این پادکست، من «مهدی شفا» یک‌ کتاب‌ غیر‌‌داستانی مربوط‌ به ژنتیک، فرگشت، مغز، ذهن و‌رفتار‌انسان ‌رو خلاصه و‌ خدمت شما تعریف میکنم. این تلاشی است در جهت افزایش آگاهی، تفکر نقادانه و‌ سنجشگر و‌ بینش علمی در بین فارسی زبانان.    Summarizing and explaining books related to human brain, biology, Genetics, evolution and behavior.  Trying to promote scientific and critical thinking among Farsi-speaking people. 

در طول این پادکست، من «مهدی شفا» یک‌ کتاب‌ غیر‌‌داستانی مربوط‌ به ژنتیک، فرگشت، مغز، ذهن و‌رفتار‌انسان ‌رو خلاصه و‌ خدمت شما تعریف میکنم. این تلاشی است در جهت افزایش آگاهی، تفکر نقادانه و‌ سنجشگر و‌ بینش علمی در بین فارسی زبانان.&nbsp; &nbsp; Summarizing and explaining books related to human brain, biology, Genetics, evolution and behavior.&nbsp; Trying to promote scientific and critical thinking among Farsi-speaking people.&nbsp;

Houshivar Podcast

🎙️INTERVIEWS DE FEMMES AVEC UN MÉTIER OU UNE ACTIVITÉ DE MONTAGNE ⛰️


Souvent, le choix d'un mode de vie commence par une passion. Et avec Elles au Sommet, il s’agit de la montagne.
Secouriste, gardien de refuge, traileur, alpiniste, ces métiers sont peu connus et présentent des destins hors du commun.
 
Et si nous parlions au féminin ? 
➡️ Ça nous donne le podcast "Elles au Sommet".
 
Chaque semaine, "Elles au Sommet" part à la rencontre d'une femme exerçant un métier ou une activité liée à la montagne. Ce partage d'expériences permet l'émergence d'une communauté de femmes en montagne, transmettant passions, courage et authenticité à celles qui souhaiteraient se lancer dans de belles aventures montagneuses, tout en inspirant les autres.
 
Le premier épisode est disponible le 1er mai.⭐
Toutes les actualités du podcast ainsi que du contenu montagne sont relayés sur la page Instagram  https://www.instagram.com/elles_au_sommet/. 
 
Et toi, n'as-tu pas envie de découvrir ces destins fascinants à travers le podcast Elles au Sommet ?
Hébergé par Ausha. Visitez ausha.co/fr/politique-de-confidentialite pour plus d'informations.

🎙️INTERVIEWS DE FEMMES AVEC UN MÉTIER OU UNE ACTIVITÉ DE MONTAGNE ⛰️ Souvent, le choix d'un mode de vie commence par une passion. Et avec Elles au Sommet, il s’agit de la montagne. Secouriste, gardien de refuge, traileur, alpiniste, ces métiers sont peu connus et présentent des destins hors du commun. Et si nous parlions au féminin ? ➡️ Ça nous donne le podcast "Elles au Sommet". Chaque semaine, "Elles au Sommet" part à la rencontre d'une femme exerçant un métier ou une activité liée à la montagne. Ce partage d'expériences permet l'émergence d'une communauté de femmes en montagne, transmettant passions, courage et authenticité à celles qui souhaiteraient se lancer dans de belles aventures montagneuses, tout en inspirant les autres. Le premier épisode est disponible le 1er mai.⭐ Toutes les actualités du podcast ainsi que du contenu montagne sont relayés sur la page Instagram https://www.instagram.com/elles_au_sommet/. Et toi, n'as-tu pas envie de découvrir ces destins fascinants à travers le podcast Elles au Sommet ? Hébergé par Ausha. Visitez ausha.co/fr/politique-de-confidentialite pour plus d'informations.

🎙️INTERVIEWS DE FEMMES AVEC UN MÉTIER OU UNE ACTIVITÉ DE MONTAGNE ⛰️


Souvent, le choix d'un mode de vie commence par une passion. Et avec Elles au Sommet, il s’agit de la montagne.
Secouriste, gardien de refuge, traileur, alpiniste, ces métiers sont peu connus et présentent des destins hors du commun.
&nbsp;
Et si nous parlions au féminin ? 
➡️ Ça nous donne le podcast "Elles au Sommet".
&nbsp;
Chaque semaine, "Elles au Sommet" part à la rencontre d'une femme exerçant un métier ou une activité liée à la montagne. Ce partage d'expériences permet l'émergence d'une communauté de femmes en montagne, transmettant passions, courage et authenticité à celles qui souhaiteraient se lancer dans de belles aventures montagneuses, tout en inspirant les autres.
&nbsp;
Le premier épisode est disponible le 1er mai.⭐
Toutes les actualités du podcast ainsi que du contenu montagne sont relayés sur la page Instagram &nbsp;https://www.instagram.com/elles_au_sommet/. 
&nbsp;
Et toi, n'as-tu pas envie de découvrir ces destins fascinants à travers le podcast Elles au Sommet ?
Hébergé par Ausha. Visitez ausha.co/fr/politique-de-confidentialite pour plus d'informations.

Elles au Sommet

Встретились как-то биолог, математик и географ и давай рассказывать про научные открытия и связанные с ними истории. Тема каждого выпуска — слово или понятие, которое мы препарируем со всех сторон.

Предметный Указатель

Découvrez les récits captivants des personnalités, célèbres ou confidentielles, qui façonnent l'univers de l'intelligence artificielle et de la technologie.<hr> Hébergé par Acast. Visitez <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> pour plus d'informations.

Découvrez les récits captivants des personnalités, célèbres ou confidentielles, qui façonnent l'univers de l'intelligence artificielle et de la technologie. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Découvrez les récits captivants des personnalités, célèbres ou confidentielles, qui façonnent l'univers de l'intelligence artificielle et de la technologie. Hébergé par Acast. Visitez <a href="https://acast.com/privacy" rel="noopener noreferrer">acast.com/privacy</a> pour plus d'informations.

Defend Stories

Chris & Steve are two childhood friends who lost touch after High School but reunited 30-something years later and discovered they both had a deep interest in the same (arguably not so) deep sh*t. So, they decided to start a podcast to talk about it! Steve is a lawyer and Chris works in insurance, but when they're not doing their day jobs they like to tackle topics such as UFOs / UAPs, Ancient Mysteries, Alternative History, Societal Trends, and whatever else seems interesting and cool.

Chris &amp; Steve are two childhood friends who lost touch after High School but reunited 30-something years later and discovered they both had a deep interest in the same (arguably not so) deep sh*t. So, they decided to start a podcast to talk about it! Steve is a lawyer and Chris works in insurance, but when they're not doing their day jobs they like to tackle topics such as UFOs / UAPs, Ancient Mysteries, Alternative History, Societal Trends, and whatever else seems interesting and cool.

(Not So) Deep Sh*t with Chris & Steve

A podcast about the messy, beautiful ways grown-ups grow up. Leaders, learning experts and developmental researchers come together to explore turning science into the day-to-day practice of adult development in teams, homes, organisations, and life. 
Dr Alis Anagnostakis is an adult development researcher, group learning facilitator and founder of the Vertical Development Institute. Her highest hope as a researcher-practitioner is to help support the growth of conscious, mature and future-fit leaders and to bring the tools of vertical development into day-to-day to day life. <a href="https://www.verticaldevelopment.education?utm_medium=podcast">www.verticaldevelopment.education</a>

A podcast about the messy, beautiful ways grown-ups grow up. Leaders, learning experts and developmental researchers come together to explore turning science into the day-to-day practice of adult development in teams, homes, organisations, and life. Dr Alis Anagnostakis is an adult development researcher, group learning facilitator and founder of the Vertical Development Institute. Her highest hope as a researcher-practitioner is to help support the growth of conscious, mature and future-fit leaders and to bring the tools of vertical development into day-to-day to day life. www.verticaldevelopment.education

A podcast about the messy, beautiful ways grown-ups grow up. Leaders, learning experts and developmental researchers come together to explore turning science into the day-to-day practice of adult development in teams, homes, organisations, and life. 
Dr Alis Anagnostakis is an adult development researcher, group learning facilitator and founder of the Vertical Development Institute. Her highest hope as a researcher-practitioner is to help support the growth of conscious, mature and future-fit leaders and to bring the tools of vertical development into day-to-day to day life. <a href="https://www.verticaldevelopment.education?utm_medium=podcast" rel="noopener noreferrer">www.verticaldevelopment.education</a>

Science Podcasts / Page 523

Cinética

Las Energías renovables

SLAS Discovery Author Insights

Razones siderales

Jouheva joustavuus matematiikassa

Podcast Jc

In the Active Site

Las científicas del coronavirus

Algo2Go

Podcastmais

High Maintenance

Episodio Sociedades

My. Psikoloji

Los Bioinges Podcast

Addiction Practice Pod

Unter 4 Augen - der Wissenschaftspodcast der Ophthalmologie

Radio Amonite

STEMFellows

EURÊKA | Les super-pouvoirs de notre cerveau

Caroberts88877

认知心理学：开启认识世界的全新大门

A lo legal: Derecho y actualidad

Vogelboekenpodkast

Politikon

سیڤی لاین

San Diego Weather Daily

Lurt av læreboken?

Malaria Vaccine

De 0 a 100 na Aquicultura

Houshivar Podcast

Elles au Sommet

Предметный Указатель

Defend Stories

(Not So) Deep Sh*t with Chris & Steve

The Developmental

On a First Name Basis

Las Crónicas del Viajero

Body Stones and Other Bodies

Animal Welfare Conversations

Talking Transplant

Herbivores , carnivores and omnivores

Wild Beings Podcast

Harvest Knowledge: Cultivating Minds in the Field of Agriculture

Opium Bird

Editors

自我感与股市

Sustainability Savvy

talkONtalk

پادکست فارسی همین جوری

Holiday Meteor Shower Magic-A Celestial Waltz with the Geminids